2IDYearPubNameAuthor'sGenderCountrywhere thestudy wasconductedRespondentsTypes ofMethodsAimFindings012020Djekic, Demir,Lin Shi, HaraldBrolin, FridaCarlsson,CharlotteSärnqvist, OttoSavolainen,Yang CaoMale,female,male,female,female,male,maleSwedenAspirin andcholesterol-loweringdrugs like Lipitorwere required forparticipants over theage of 18, as well asstable IHD and PCIconducted more thana month before thetrial's start date.There was a one-year-old age limit forexclusion.prospective,open-label,randomized, controlledcrossoverclinical trialThis study researched howTMAO, choline, l-carnitine,and acetyl-carnitine affectedthe plasma metabolome andhow the gut microbiotaaffected LDL-C andcardiovascular risk factors.As part of the study, theauthors employed a 1:1 ratioof gut microbiota and plasmametabolome at baseline,which was aimed to ensurethat the two sequences werein harmony with one another.There were four clinicalfollow-up visits throughoutthe experiment, one beforeand after each interventionperiod.The most crucial outcome measure wasthe difference in plasma oxidized LDL-Cbetween the two diet groups. Participants'changes in cardiometabolic risk factorswere compared in the secondaryoutcomes. Cardiometabolic benefits of afour-week VD are superior to those of anisocaloric MD in patients with ischemicheart disease who are getting optimalmedical treatment, according to the studyresults. LDLC oxidation, LDL-C, totalcholesterol, and body weight were lower
